BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zhu Y, Moriarty JP, Swanson KM, Takahashi PY, Bielinski SJ, Weinshilboum R, Wang L, Borah BJ. A model-based cost-effectiveness analysis of pharmacogenomic panel testing in cardiovascular disease management: preemptive, reactive, or none? Genet Med 2021;23:461-70. [PMID: 33041335 DOI: 10.1038/s41436-020-00995-w] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Zago PMJJ, da Silva GR, Amaral EC, Barboza LN, Braga FA, Lorençone BR, Marques AAM, Moreno KGT, Leite PRT, Veiga AA, de Souza LM, Souza RIC, Dos Santos AC, Ribeiro-Paes JT, Gasparotto Junior A, Lívero FADR. Multiple Risk Factors for Heart Disease: A Challenge to the Ethnopharmacological Use of Croton urucurana Baill. Evid Based Complement Alternat Med 2021;2021:6580458. [PMID: 34819983 DOI: 10.1155/2021/6580458] [Reference Citation Analysis]
2 Del Toro-pagán NM, Matos A, Bardolia C, Michaud V, Turgeon J, Amin NS. Pharmacist assessment of drug-gene interactions and drug-induced phenoconversion in major depressive disorder: a case report. BMC Psychiatry 2022;22. [DOI: 10.1186/s12888-021-03659-4] [Reference Citation Analysis]
3 Brunette CA, Vassy JL. The role of SLCO1B1 genotyping in lowering cardiovascular risk. Pharmacogenomics 2021;22:649-56. [PMID: 34196599 DOI: 10.2217/pgs-2021-0075] [Reference Citation Analysis]
4 Cohn I, Manshaei R, Liston E, Okello JBA, Khan R, Curtis MR, Krupski AJ, Jobling RK, Kalbfleisch K, Paton TA, Reuter MS, Hayeems RZ, Verstegen RHJ, Goldman A, Kim RH, Ito S. Assessment of the Implementation of Pharmacogenomic Testing in a Pediatric Tertiary Care Setting. JAMA Netw Open 2021;4:e2110446. [PMID: 34037732 DOI: 10.1001/jamanetworkopen.2021.10446] [Reference Citation Analysis]
5 Qi G, Zhang J, Han C, Zhou Y, Li D, Ma P. Genetic landscape of 125 pharmacogenes in Chinese from the Chinese Millionome Database. Sci Rep 2021;11:19222. [PMID: 34584183 DOI: 10.1038/s41598-021-98877-x] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Pandi MT, Koromina M, Vonitsanos G, van der Spek PJ, Patrinos GP, Mitropoulou C. Development of an optimized and generic cost-utility model for analyzing genome-guided treatment data. Pharmacol Res 2022;:106187. [PMID: 35331864 DOI: 10.1016/j.phrs.2022.106187] [Reference Citation Analysis]
7 Dagli-Hernandez C, Zhou Y, Lauschke VM, Genvigir FDV, Hirata TDC, Hirata MH, Hirata RDC. Pharmacogenomics of statins: lipid response and other outcomes in Brazilian cohorts. Pharmacol Rep 2021. [PMID: 34403130 DOI: 10.1007/s43440-021-00319-y] [Reference Citation Analysis]
8 Brunette CA, Dong OM, Vassy JL, Danowski ME, Alexander N, Antwi AA, Christensen KD. A Cost-Consequence Analysis of Preemptive SLCO1B1 Testing for Statin Myopathy Risk Compared to Usual Care. J Pers Med 2021;11:1123. [PMID: 34834475 DOI: 10.3390/jpm11111123] [Reference Citation Analysis]
9 Luzum JA, Petry N, Taylor AK, Van Driest SL, Dunnenberger HM, Cavallari LH. Moving Pharmacogenetics Into Practice: It's All About the Evidence! Clin Pharmacol Ther 2021. [PMID: 34101169 DOI: 10.1002/cpt.2327] [Reference Citation Analysis]
10 Sakon CM, Tillman EM. Pharmacogenomics: a tool to improve medication safety and efficacy in patients with cystic fibrosis. Pharmacogenomics 2022. [PMID: 35670256 DOI: 10.2217/pgs-2022-0025] [Reference Citation Analysis]